# HM2023-11 PH I study of ven/aza or ven in combination with ziftomenib (KO-539) or 7+3 induction chemo with ziftomenib for AML pts

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male or Female
**Age Group:** 18 years and over
This study is also accepting healthy volunteers

**Inclusion Criteria:**

- newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) with specific mutation (study staff will review) - able to walk and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - adequate liver, renal, and cardiac function - women and men of child bearing age must follow specific requirements for birth control

**Exclusion Criteria:**

- other types of leukemia - active involvement of central nervous system - clinically active human immunodeficiency virus, active hepatitis B or active hepatitis C infection - women who are pregnant or breast feeding - additional criteria (study staff will review)

## Conditions & Interventions

**Conditions:**
Cancer
**Keywords:**
Clinics and Surgery Center (CSC), Acute Leukemia, Acute Myeloid Leukemia, AML, Leukemia

## More Information

**Description:** There are certain genetic changes in the leukemia cell thought to drive the disease in patients with acute myeloid leukemia. Ziftomenib is an investigational drug that blocks the menin pathway in hopes of preventing or slowing the leukemia cells from growing and dividing. The purpose of this study is to determine the safe dose of an investigational new drug (ziftomenib) used in combination with other study drugs i.e., venetoclax and azacitidine, to treat cancer. This will include an evaluation of side effects associated with ziftomenib in combination with the other study drugs and how ziftomenib works in combination with the other study drugs (venetoclax and azacitidine).
**Study Contact:** Mark Juckett - juck0001@umn.edu
**Principal Investigator:** Mark Juckett
**IRB Number:** SITE00001987